SPIRE HEALTHCARE GROUP PLC (SPI) — Investment Research Note

Executive summary

Spire Healthcare is the UK's second-largest private hospital operator, running 38 hospitals and ~60 clinics with a payor mix of PMI (~44%), NHS (~25%), and self-pay (~22%). Across the covered period (2020–2026 YTD), the business rebuilt from pandemic-era NHS support contracts into a private-led growth story — revenue expanded from £919m (FY20) to £1,511m (FY24), Adjusted EBITDA rose from £161m to £260m, and net bank debt / EBITDA leverage fell from 3.9x to 2.0x — but momentum has stalled in 2025-26 as NHS commissioning weakened and wage/NI inflation ate margin. The single most important valuation point today is that the board has been running an active strategic review since Sept 2025 (Bridgepoint and Triton walked away in March 2026); the price now discounts a partial-fit outcome rather than a takeout premium, and the freehold estate valued by the company at >£1.4bn effectively floors intrinsic value near the current market cap.

Fair value estimate

Range: 240p – 300p per share (£960m – £1,200m market cap).

Methodology — blended EV/EBITDA multiple with real-estate NAV cross-check:

• Base case (EV/EBITDA): FY26 Adjusted EBITDA guided "broadly in line with FY25" (£270m target per profit forecast in the 14-May-2026 trading update 2026-05-14 FY26 trading update). Applying 7.0–7.5x to £270m of Group EBITDA yields EV of £1,890–£2,025m. Deducting net bank debt of £357m (H1 25) 2025-07-31 half-year gives equity of £1,533–£1,668m, or 383–416p — but this multiple treats leases as operating rather than debt.
• After-lease EV/EBITDA: Total borrowings including £915m of IFRS-16 lease liabilities push all-in leverage well above the covenant view. On a covenant-basis LTM EBITDA (~£170m pre-IFRS-16, 2025-07-31 half-year, note 18), a 6–7x multiple gives equity of ~£660m–£830m or 165–207p per share.
• NAV cross-check: Freehold portfolio "valued at more than £1.4bn" 2025-07-31 CEO commentary; adjusting for net bank debt of £357m gives a property-backed floor of ~£1.05bn or ~260p per share. The Cheshire sale-leaseback (Dec 2021) crystallised a ~£23m gain on a single hospital, validating asset value.
• M&A signal: Bridgepoint / Triton withdrew in March 2026 2026-03-23 strategic review update; the share price fell to 146p on that news vs 249p peak in Sept 2025, implying the market previously priced ~230–260p as a probable takeout value.

Central fair value: 270p, implying market cap ~£1,080m and ~15% upside from 235p. This blends operating value (~250p) with a modest strategic-review optionality.

Sector context

• ICB Health Care classification is confirmed.
• Spire is UK-focused private acute-care, closest analogues are pan-European hospital groups: Fresenius (Helios), Mediclinic (formerly listed, taken private 2023), Ramsay Health Care (ASX). There are no direct UK-listed acute-hospital peers post-Mediclinic delisting; adjacent listed comparables include Nuffield Health (not listed) and diagnostic operators like Assura (REIT), Primary Health Properties.
• Quality profile: 98% of inspected hospitals rated Good/Outstanding — above sector average. Growth (mid-single-digit) and leverage (2.0x net bank / 2x incl. lease covenant) are in-line with hospital peers; margins (17% EBITDA) are lower than European mainland peers (~19–22%).

Investment thesis (3 bullets)

1. Strategic review provides valuation floor with optionality. With Bridgepoint/Triton withdrawn but the Board explicitly stating it "remains in discussions with other parties" 2026-03-23 strategic review update, and the "Board is pleased with the progress made in implementing strategic and efficiency initiatives and believes that these, together with Spire's freehold property valued at >£1.4bn and a well-invested asset base, are not yet reflected by the market in full" 2025-07-31 half-year, holders benefit from either a re-emergent bid or an eventual re-rating as the private strategy delivers.
2. NHS waiting list tailwind combined with structural PMI growth. NHS waiting lists remain elevated (~7m+), Government has re-confirmed independent sector as a key partner, and PMI covered lives are still growing — the 2025 half-year showed NHS revenue +16.2% y/y with high orthopaedic mix and Private revenue trends stabilising 2025-07-31 half-year. Self-pay volumes improved sequentially through H2 25 2025-12-03 trading update.
3. £30m FY26 savings programme underpins EBITDA resilience. Group is targeting FY26 EBITDA "broadly in line with FY25" despite ongoing NI/NMW headwinds; £30m of new savings for FY26 have "majority of initiatives underpinned" 2026-05-14 FY26 trading update. Patient Support Centres are now driving 5x faster call response with ~10% lower staffing 2025-07-31 half-year, validating the operating-leverage story if volumes return.

Key risks (3 bullets)

1. NHS commissioning cuts driving FY25 guidance to bottom of range. ICB budgetary restrictions caused NHS activity slowdown and the group guided FY25 EBITDA to "around the bottom end" of £270-285m range 2025-12-03 trading update. The 2026/27 NHS tariff uplift "falls significantly short of the prevailing rate of inflation" per the December 2025 update — a structural squeeze on the NHS segment.
2. Strategic review is a source of value but also of failure risk. Two PE parties have already walked away 2026-03-23 strategic review update; failure to conclude a deal from remaining discussions could see the share price retest March 2026 lows near 146p. Additionally, Rule 28 profit forecasts constrain guidance flexibility while the offer period continues.
3. Structural wage inflation squeezing margin. H1 25 EBITDA margin fell 33bps to 16.8% despite revenue growth of 4.9% due to April 2025 NI/NMW rises 2025-07-31 half-year. Restructuring of ~400 permanent roles was booked as £9.6m adjusting item, and the £18.9m cumulative transformation cost since 2021 is running longer than originally planned (now expected to complete late 2027).

Operating leverage

Spire has meaningful but currently disappointing operating leverage. Hospital operations carry a large fixed cost base — property leases, clinical infrastructure, central overhead — that management sizes as roughly 40% of revenue in staff costs plus £102m of annual lease payments (FY24) 2025-03-06 final results. Gross margin of ~46% and Adjusted EBITDA margin of 17% imply that at current scale, an incremental £100m of revenue at a 60-65% contribution margin should add ~£60m to EBITDA (a >20% EBITDA uplift on ~5-7% incremental revenue). However, in practice this leverage is currently being consumed by wage inflation: H1 25 delivered 4.9% comparable revenue growth but only 2.8% EBITDA growth, and FY26 guidance implies flat EBITDA on likely mid-single-digit revenue growth 2026-05-14 FY26 trading update. The Patient Support Centre programme and £30m FY26 savings target are the mechanisms by which management is attempting to convert future volume into disproportionate profit — inflection point would be sustained NHS/private volume recovery combined with easing wage inflation, potentially FY27 onward. Hospital-level margin of 17.8% (H1 25) vs a medium-term target above 21% shows the theoretical upside if leverage converts.

Value-trap signals

• Repeated EBITDA guidance movements toward lower end, with H1 22–FY23 delivering strongly but FY25 now guided to bottom end of range 2025-12-03 trading update.
• Two PE bidders walked away in the same strategic review, suggesting valuation gap between board expectations and market clearing price 2026-03-23 strategic review update.
• NHS margin structurally under pressure from ICB budget constraints and below-inflation 2026/27 tariff proposal 2025-12-03 trading update.
• Persistent Paterson legacy costs — additional £4.6m provision top-up in H1 24, ongoing legal fees into 2025 2025-07-31 half-year.
• Bank debt refinancing risk — August 2028 maturity, £425m facility 2025-12-03 trading update. Not imminent but a watch item.

Earnings vs. expectations

• FY23 (2024-02-29): Delivered Revenue £1,359m, Adj EBITDA £234m — met/beat guidance; EBITDA margin +90bps.
• FY24 (2025-03-06): Guidance was for ROCE improvement, margin improvement. Delivered Revenue £1,511m, Adj EBITDA £260m — met previously communicated targets. Consensus was ~£258m — slight beat.
• H1 25 (2025-07-31): "Trading in line with market expectations" — consensus £276.1m for FY25 2025-07-31 half-year — in-line.
• Dec 2025 update: Guided FY25 EBITDA to "around the bottom end of £270-285m" — implicit guidance cut by ~£6m to consensus.
• FY26 outlook (May 2026): "Broadly in line" with FY25 (~£270m) — implies flattish vs prior "in line or slightly ahead" language.

Pattern: Historic delivery has been solid (met-to-beat 2023-24), but 2025-26 shows a clear pattern of guidance drift toward the lower end and softening forward outlook. Not a serial misser, but momentum is negative.

Conviction

Rating: 3 – Moderate.

• Supporting factors: (1) Clear disclosure and consistent Adjusted EBITDA / covenant EBITDA reporting; (2) Freehold property backstop provides an anchor for downside case; (3) Strategic review process itself provides a market-tested read on takeout value (~230-260p range implied by pre-March-2026 trading).
• Limiting factors: (1) Strategic review outcome is highly binary and uncertain — a bid could re-emerge or the review could quietly close; (2) The gap between covenant EBITDA (£170m) and reported adjusted EBITDA (£260m) — driven by IFRS-16 lease treatment — makes multiple choice materially affect fair value.

Driver scoring rationale

• ai_beneficiary (8): Zero AI-receiver angle. Company uses AI as a tool ("AI software for MRI scanners") but captures no meaningful AI-driven revenue. Structural exposure is essentially nil.
• operating_leverage (45): Fixed cost base is real (hospitals, leases, central) but current data shows leverage being consumed by wage inflation rather than delivered. Would score higher if revenue inflection materialised.
• earnings_surprise_trend (40): Recent guidance drift to bottom of range and softer FY26 outlook argues for slight miss bias, offsetting 2023-24 delivery track record.
• cyclicality (35): Healthcare is defensive but NHS commissioning cycle and PMI/self-pay elasticity add moderate cyclicality.
• moat (50): Scale (38 hospitals, second-largest UK private operator), quality ratings, freehold asset base — but limited pricing power vs PMIs and NHS.
• leverage (58): Net bank debt / covenant EBITDA at 2.2x is manageable but IFRS-16 leases push structural leverage higher; 2028 refinancing is a live consideration.
• earnings_quality (55): Generally clean, but recurring "adjusting items" (Paterson, restructuring) run at ~£10-15m/yr and Adjusted EBITDA excludes ~£100m of annual rent that IFRS-16 reclassifies.
• management_quality (55): Delivered on the transformation programme and Vita integration; strategic review with two withdrawals raises questions on process; CEO Justin Ash has been consistent in messaging.
• growth_momentum (45): Revenue growth mid-single-digit but EBITDA growth stalling; H1 25 EBITDA +2.8% comparable is weakest print in the covered period.

Overall score rationale

Spire scores poorly against this investor's specific profile: essentially zero AI-receiver exposure (largest single weight in the framework), moderate but currently-not-delivering operating leverage, fair-ish valuation with a property floor but no obvious catalyst absent a resurrected bid, and acceptable-but-not-fortress balance sheet. It's a defensive UK healthcare operator with real assets and a viable business — but this investor is explicitly looking for the AI-cycle upside kicker that Spire simply doesn't have.

Overall score: 260 / 1000.